var data={"title":"Buprenorphine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Buprenorphine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5768?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">see &quot;Buprenorphine: Drug information&quot;</a> and <a href=\"topic.htm?path=buprenorphine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Buprenorphine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50624628\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Addiction Medications With Benzodiazepines or CNS Depressants Safety Alert</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Based on additional review, the FDA is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or CNS depressants. The combined use of these drugs increases the risk of serious adverse reactions including overdose and death; however, the harm caused by untreated opioid addiction usually outweighs these risks. Careful medication management by health care providers can reduce these risks. The FDA is requiring this information to be added to the buprenorphine and methadone drug labels along with detailed recommendations for minimizing the use of medication-assisted treatment (MAT) drugs and benzodiazepines together.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm576755.htm?elqTrackId=e65014b0f99945b087eaca49bf2c9d77&elq=9ebe61fc045c43c89c2c3b3e1f4fb4e0&elqaid=531&elqat=1&elqCampaignId=191&amp;token=6l/TlH+0N8pHeLo/7CcHeqMqrSvgEFU7xeoVUgoMtgvo3T4PnW2yrqUJEZx/5F9E9bfHfOyREIuV8VXi8KwbAljHoHNA9ZfnE/OPaou+JihEhacBZTVCtsSd3DRBTvqsWrBgGPWXSAUgPfIihKRMgXBNTCGx3jhdljwc9zCZIaIbpa3h9OylnoDeUSJfCypTgN+ZcOfa9DMSqrnhcWy2SFuInw5gT1mtcb4aCvCj4ZTZN+TmFeow+ef2Rwt4BYoO&amp;TOPIC_ID=12918\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm576755.htm?elqTrackId=e65014b0f99945b087eaca49bf2c9d77&amp;elq=9ebe61fc045c43c89c2c3b3e1f4fb4e0&amp;elqaid=531&amp;elqat=1&amp;elqCampaignId=191</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11370705\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental exposure (buccal film, transdermal patch):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental exposure to even one dose of buprenorphine, especially by children, can result in a fatal overdose of buprenorphine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse (buccal film, immediate-release injection, transdermal patch):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing buprenorphine and monitor all patients regularly for the development of these behaviors or conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression (buccal film, immediate-release injection, transdermal patch):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of buprenorphine. Monitor for respiratory depression, especially during initiation of buprenorphine or following a dose increase. Misuse or abuse of buprenorphine by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film or transdermal system will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome (buccal film, immediate-release injection, transdermal patch):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk associated with insertion and removal (subdermal implant):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Insertion and removal of buprenorphine implant are associated with the risk of implant migration, protrusion, and expulsion resulting from the procedure. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion, and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risks associated with insertion and removal, buprenorphine implant is available only through a restricted program called the Probuphine REMS Program. All healthcare providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing buprenorphine implants. Patients must be monitored to ensure that the implant is removed by a healthcare provider certified to perform insertions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants (buccal film, immediate-release injection, transdermal patch):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of buprenorphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of serious harm or death with intravenous administration (extended-release injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious harm or death could result if extended-release injection is administered intravenously. The injection forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thromboembolic events, including life-threatening pulmonary emboli if administered intravenously.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of serious harm or death that could result from intravenous self-administration, buprenorphine extended-release injection is only available through a restricted program called the Sublocade REMS Program. Healthcare settings and pharmacies that order and dispense buprenorphine extended-release injection must be certified in this program and comply with the REMS requirements.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143056\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Belbuca;</li>\n      <li>Buprenex;</li>\n      <li>Butrans;</li>\n      <li>Probuphine Implant Kit;</li>\n      <li>Sublocade</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143057\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Belbuca;</li>\n      <li>Butrans</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051379\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Narcotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Opioid Partial Agonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16425058\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neonatal abstinence syndrome (NAS):</b> Very limited data available: Full-term neonates: Sublingual solution (0.075 mg/mL): Initial: 5.3 mcg/kg/dose every 8 hours; dosing based on birth weight; may increase dose in 25% increments based on targeted NAS scores; a rescue dose of 50% of the previous dose may be used for inadequate control between scheduled doses; once a maximum daily dose of 60 mcg/kg/day reached, phenobarbital therapy may be added. After 3 days of dose stabilization, buprenorphine may be weaned based on NAS scores using 10% daily dose reductions. Dosing based on an open-label comparative trial with morphine (each treatment group, n=12); in the clinical trial, doses were increased if a single NAS score was &ge;12 or NAS scale scores &ge;24 total on three measures; neonates with maternal concomitant benzodiazepine or chronic alcohol abuse were excluded from the trial; results showed a significant decrease in length of NAS treatment and hospital stay compared to morphine treatment arm (Kraft, 2011). In the pilot trial, a lower initial dose of sublingual buprenorphine (4.4 mcg/kg/dose every 8 hours) was used; clinically the majority of patients had NAS symptoms controlled; no differences in outcome variables (length of treatment and hospital) were detected and pharmacokinetic analysis showed &gt;98% of serum concentrations were less than the target concentration needed to control abstinence symptoms in adults (Kraft, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051372\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">see &quot;Buprenorphine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Dose should be titrated to appropriate effect.</b> Use <sup>1</sup>/<sub>2</sub> of the dose listed in patients with pre-existing respiratory depression, decreased respiratory reserve, hypoxia, hypercapnia, significant COPD, or cor pulmonale, and in those receiving medications with CNS or respiratory depressant effects. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Moderate to severe pain:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 2-12 years: IM, slow IV injection: 2-6 <b>mcg</b>/kg every 4-6 hours; <b>Note:</b> 3 mcg/kg/dose has been most commonly studied; not all children have faster clearance rates than adults; some children may require dosing intervals of every 6-8 hours; observe clinical effects to establish the proper dosing interval </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: IM, slow IV injection: Initial: Opioid-naive: 0.3 mg every 6-8 hours as needed; initial dose may be repeated once in 30-60 minutes if clinically needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Opioid dependence:</b> <b> Note:</b> Do not start induction with buprenorphine until objective and clear signs of withdrawal are apparent (otherwise withdrawal may be precipitated). Adolescents &ge;16 years: Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Induction: Target range: 12-16 mg/day (doses during one induction study used 8 mg on day 1, followed by 16 mg on day 2; other studies accomplished induction over 3-4 days). Treatment should begin at least 4 hours after last use of heroin or short-acting opioid, preferably when first signs of withdrawal appear. Titrating dose to clinical effect should be done as rapidly as possible to prevent undue withdrawal symptoms and patient drop-out during the induction period. There is little controlled experience with induction in patients on methadone or other long-acting opioids; consult expert physician experienced with this procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance: <b>Note:</b> Patients should be switched to the buprenorphine/naloxone combination product for maintenance and for unsupervised therapy; initial target dose: 12-16 mg/day; then adjust dose in 2-4 mg increments/decrements to a dose that adequately suppresses opioid withdrawal; usual range: 4-24 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Moderate to severe pain:</b> IM, slow IV injection: Initial: Opioid-naive: 0.3 mg every 6-8 hours as needed; initial dose may be repeated once in 30-60 minutes if clinically needed; <b>Note:</b> In adults, single doses of up to 0.6 mg administered IM may occasionally be required; usual dosage range: 0.15-0.6 mg every 4-8 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Opioid dependence: Note:</b> Do not start induction with buprenorphine until objective and clear signs of withdrawal are apparent (otherwise withdrawal may be precipitated). Sublingual:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Induction: Target range: 12-16 mg/day (doses during one induction study used 8 mg on day 1, followed by 16 mg on day 2; other studies accomplished induction over 3-4 days). Treatment should begin at least 4 hours after last use of heroin or short-acting opioid, preferably when first signs of withdrawal appear. Titrating dose to clinical effect should be done as rapidly as possible to prevent undue withdrawal symptoms and patient drop-out during the induction period. There is little controlled experience with induction in patients on methadone or other long-acting opioids; consult expert physician experienced with this procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance: <b>Note:</b> Patients should be switched to the buprenorphine/naloxone combination product for maintenance and for unsupervised therapy; initial target dose: 12-16 mg/day; then adjust dose in 2-4 mg increments/decrements to a dose that adequately suppresses opioid withdrawal; usual range: 4-24 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chronic pain (moderate to severe):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Transdermal patch:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Opioid-naive patients: Initial: 5 <b>mcg</b>/hour applied once every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Opioid-experienced patients (conversion from other opioids to buprenorphine): Taper the current around-the-clock opioid for up to 7 days to &le;30 mg/day of oral morphine or equivalent before initiating therapy. Short-acting analgesics as needed may be continued until analgesia with transdermal buprenorphine is attained. There is a potential for buprenorphine to precipitate withdrawal in patients already receiving opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Patients who were receiving daily dose of &lt;30 mg of oral morphine equivalents: Initial: 5 <b>mcg</b>/hour applied once every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Patients who were receiving daily dose of 30-80 mg of oral morphine equivalents: Initial: 10 <b>mcg</b>/hour applied once every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Patient who were receiving daily dose of &gt;80 mg of oral morphine equivalents: Buprenorphine transdermal patch, even at the maximum dose of 20 <b>mcg</b>/hour applied once every 7 days, may <b>not</b> provide adequate analgesia; <b>consider the use of an alternate analgesic.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose titration (opioid-naive or opioid-experienced patients): May increase dose, based on patient&rsquo;s supplemental short-acting analgesic requirements, with a minimum titration interval of 72 hours. Maximum dose: 20 <b>mcg</b>/hour applied once every 7 days; risk for QT<sub>c</sub> prolongation increases with doses &ge;20 <b>mcg</b>/hour patch</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Discontinuation of therapy: Taper dose gradually every 7 days to prevent withdrawal; consider initiating immediate-release opioids, if needed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection, sublingual tablet: Children, Adolescents, and Adults: Use caution due to extensive hepatic metabolism; dosage adjustments recommended although no specific recommendations are provided by the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Transdermal patch: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild to moderate impairment: Initial: No dosage adjustment needed; peak plasma levels (C<sub>max</sub>) and exposure (AUC) were not increased in patients with mild to moderate hepatic impairment following intravenous administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe impairment: Not studied; consider alternative therapy with more flexibility for dosing adjustments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143032\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Film, Buccal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Belbuca: 75 mcg (60 ea); 150 mcg (60 ea); 300 mcg (60 ea); 450 mcg (60 ea); 600 mcg (60 ea); 750 mcg (1 ea, 60 ea); 900 mcg (60 ea) [contains methylparaben, propylparaben, saccharin sodium, sodium benzoate; peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Implant, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Probuphine Implant Kit: 74.2 mg (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Butrans: 5 mcg/hr (4 ea); 7.5 mcg/hr (4 ea); 10 mcg/hr (4 ea); 15 mcg/hr (4 ea); 20 mcg/hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mcg/hr (1 ea [DSC], 4 ea); 7.5 mcg/hr (4 ea); 10 mcg/hr (1 ea [DSC], 4 ea); 15 mcg/hr (1 ea [DSC], 4 ea); 20 mcg/hr (1 ea [DSC], 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Buprenex: 0.3 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.3 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sublocade: 100 mg/0.5 mL (0.5 mL); 300 mg/1.5 mL (1.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg, 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143016\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46925041\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">see &quot;Buprenorphine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Subdermal implant and subcutaneous implant both refer to Probuphine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143102\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217368\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release injection: Prescribing of the extended release injection is limited to healthcare providers who meet qualifying requirements, have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number to include on every prescription.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subdermal implant: Prescribing of implants and inserting or removing implants are limited to healthcare providers who have completed a live training program. Additionally, inserting or removing implants is limited to healthcare providers who have demonstrated procedural competency. As a prerequisite for participating in the live training program, the healthcare provider must have performed at least one qualifying surgical procedure in the last 3 months. Qualifying procedures are those performed under local anesthesia using aseptic technique and include, at a minimum, making skin incisions or placing sutures. Buprenorphine subdermal implant will only be distributed to certified prescribers through a restricted distribution program. Information concerning the insertion and removal procedures can be obtained by calling 1-844-859-6341.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet: Prescribing of tablets for opioid dependence is limited to physicians who have met the qualification criteria and have received a DEA number specific to prescribing this product. Tablets will be available through pharmacies and wholesalers which normally provide controlled substances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11370707\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Belbuca: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207932s002lbl.pdf#page=28&amp;token=yJna57LdlKYF3xzNQCjxMShOQTNJ28nlm8enwVgbiK0EDgVj1ztw29ajrGWB+v8XrmUiukFpxaPXY9rAql/hGE7o3A69/7DJ1qbgNYOoiNhfMVigZIULLoJZw1PRwW2N&amp;TOPIC_ID=12918\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207932s002lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Butrans: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021306s024lbl.pdf#page=40&amp;token=MpQwWUnCaIwd3GSrtVI+RGgno56tItc9a50aSpG0sYLkffSG2/ESUvfadbFaiNafx+oJQPAjwssrOLDSMpPL20qx8C0PeKpkibkx2kRcZuE/LCF36esWAadzz1QXgrf7&amp;TOPIC_ID=12918\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021306s024lbl.pdf#page=40</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Probuphine implant: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204442s006lbl.pdf#page=49&amp;token=ZCAkgbPEfVeG4SvowmM6seH13Z2pWRNyDsBPwstSOdQ2J9aXlA9OAKVqSjzjQOtT2aFf66uDvHFtf7Skj5n9hq89ldXtNIAeh4d5I86kizupCv2ilz2Nt7/K1TKHR/fd&amp;TOPIC_ID=12918\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204442s006lbl.pdf#page=49</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublocade: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf#page=40&amp;token=6GJwMZET+EQbNuw3hvuMuubpqISe8/SjtvO+ye0BgBVUQM3OzDEN8zz/QQ2u0GIbaWVOODKBXSXp5OyGWYIz4hRekOqqbE8QAxsRUm5OGG5hfXJmCQk1ricDr/rwy1U+&amp;TOPIC_ID=12918\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf#page=40</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subutex: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020732s018lbl.pdf#page=27&amp;token=x48zykbQCRmC6X9Et584UqDOfuQwPRIbW80Lr7wAAiHp4QqEgdBvk8LLvXlNRVxV3eZuwNLMwi1Vw2wkR2oFqcsLinXwJOUNmoSji98+PSbY5FztckYkbG4rXCpwAGMX&amp;TOPIC_ID=12918\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020732s018lbl.pdf#page=27</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051383\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sublingual solution: In neonates, place dose under tongue; insert pacifier to help reduce swallowing of dose (Kraft, 2008; Kraft, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sublingual tablet: Place tablet under the tongue until dissolved; do not swallow. If 2 or more tablets are needed per dose, all tablets may be placed under the tongue at once, or 2 tablets may be placed under the tongue at a time; to ensure consistent bioavailability, subsequent doses should always be taken the same way. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer via deep IM injection </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Administer slowly, over at least 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical: Transdermal patch: Apply patch to intact, nonirritated skin only. Apply to a hairless or nearly hairless skin site. If hairless site is not available, do not shave skin (as absorption from patch can be increased); hair at application site should be clipped. Prior to application, if the site must be cleaned, clean with clear water and allow to dry completely; do not use soaps, alcohol, lotions, or abrasives due to potential for increased skin absorption. Do not use any patch that has been damaged, cut, or manipulated in any way. Remove patch from protective pouch immediately before application. Remove the protective backing, and apply the sticky side of the patch to one of eight possible application sites (upper outer arm, upper chest, upper back, or the side of the chest [each site on either side of the body]). Firmly press patch in place and hold for ~15 seconds. Change patch every 7 days. Rotate patch application sites; wait &ge;21 days before reapplying another patch to the same skin site. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape. If the patch falls off during the 7-day dosing interval, dispose of the patch and apply a new patch to a different skin site. To properly dispose of Butrans&reg; patch, fold it over on itself and flush down the toilet; alternatively, seal the used patch in the provided Patch-Disposal Unit and dispose of in the trash.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143050\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release injection: Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Discard if left at room temperature (15&deg;C to 30&deg;C [59&deg;F to 86&deg;F]) for more than 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate-release injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from prolonged exposure to light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buccal film, transdermal patch, sublingual tablet: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subdermal implant: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051382\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Sublingual tablet: Treatment of opioid dependence (FDA approved in ages &ge;16 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Management of moderate to severe pain (FDA approved in ages &ge;2 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal: Management of moderate to severe chronic pain in patients requiring an around-the-clock opioid analgesic for an extended period of time (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143110\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Buprenex may be confused with Brevibloc, Bumex</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143107\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Buccal film:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, depression, dizziness, drowsiness, falling, fatigue, headache, insomnia, withdrawal syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, gastroenteritis, nausea (incidence may be increased during dose titration), vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, bruise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, muscle spasm</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, nasopharyngitis, oropharyngeal pain, sinus congestion, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Implant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, edema (at implant site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills, depression, dizziness, drowsiness, fatigue, headache, migraine, paresthesia, sedation, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (at implant site), excoriation (including scratch), pruritus (at impant site), skin lesion, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation, flatulence, nausea, toothache, upper abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (at implant site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local swelling</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, limb pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, dyspnea, oropharyngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, laceration, pain at medication pump site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache, sedation, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Miosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoventilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sublingual tablet:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, constipation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transdermal patch:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, hypertension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, depression, dizziness, drowsiness, falling, fatigue, headache, hypoesthesia, insomnia, migraine, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress, anorexia, constipation, diarrhea, dyspepsia, nausea, upper abdominal pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema, application site irritation, application site rash, local pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, joint swelling, limb pain, muscle spasm, musculoskeletal pain, myalgia, neck pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, cough, dyspnea, flu-like symptoms, nasopharyngitis, pharyngolaryngeal pain, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Rare but important or life-threatening: Abdominal discomfort, abnormal dreams, abnormal hepatic function tests, acute sinusitis, amblyopia, anaphylactic shock, angina pectoris, apnea, application site dermatitis, bradycardia, cellulitis, coma, constipation, contact dermatitis, cough, cyanosis, decreased appetite, decreased serum testosterone, depression, diplopia, diverticulitis, dyspepsia, dysphoria, dyspnea, exacerbation of asthma, excoriation, fatigue, hallucination, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis (including cytolytic), hepatorenal syndrome, hypersensitivity reaction, hypertension, hyperventilation, hypoesthesia, hypogonadism (Brennan 2013; Debono 2011), hypotension, hypoventilation, increased serum ALT, increased serum AST, injection site reaction, intestinal obstruction, jaundice, laceration, loss of consciousness, memory impairment, mental deficiency, mental status changes, migraine, miosis, musculoskeletal pain, nasal congestion, neck pain, orthostatic hypotension, paresthesia, prolonged Q-T interval on ECG, psychosis, respiratory distress, rhinorrhea, seizure, skin rash, slurred speech, syncope, tachycardia, tooth abscess, toothache, tremor, urinary incontinence, urinary retention, vasodilatation, visual disturbance, weakness, Wenckebach period on ECG, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143038\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to buprenorphine or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buccal film, immediate-release injection, transdermal patch: Additional contraindications: Significant respiratory depression; acute or severe asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Transdermal patch and buccal film (Additional contraindications; not in US labeling): Hypersensitivity to other opioids; suspected surgical abdomen (eg, acute appendicitis or pancreatitis); mild, intermittent or short duration pain that can otherwise be managed; management of acute pain, including use in outpatient or day surgeries; management of perioperative pain relief, or in other situations characterized by rapidly varying analgesic requirements; acute respiratory depression; hypercapnia; cor pulmonale; obstructive airway (other than asthma); status asthmaticus; acute alcoholism or alcohol dependence; delirium tremens; convulsive disorders; severe CNS depression; increased cerebrospinal or intracranial pressure; head injury; concurrent use or use within 14 days of MAOIs; myasthenia gravis; severe hepatic insufficiency; opioid dependent patients and for opioid withdrawal treatment; pregnancy or during labor and delivery; breastfeeding; known or suspected oral mucositis (buccal film only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143020\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic events: Hepatitis has been reported; hepatic events ranged from transient, asymptomatic transaminase elevations to hepatic failure; in many cases, patients had preexisting hepatic impairment. Monitor liver function tests in patients at increased risk for hepatotoxicity (eg, history of alcohol abuse, preexisting hepatic dysfunction, IV drug abusers) prior to and during therapy. Remove buprenorphine subdermal implant if signs and symptoms of buprenorphine toxicity develop concurrent with hepatic impairment. If signs and symptoms of toxicity or overdose occur within 2 weeks of extended-release injection, removal of the depot may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity, including bronchospasm, angioneurotic edema, and anaphylactic shock, have been reported. The most common symptoms include rash, hives, and pruritus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Subdermal implant: Infection may occur at site of insertion or removal, with excessive palpation shortly after insertion and improper removal increasing the risk. Examine the insertion site 1 week following insertion for signs of infection or problems with wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Buprenorphine has been observed to cause QTc prolongation. Do not exceed a dose of 900 mcg every 12 hours buccal film or one 20 <b>mcg</b>/hour transdermal patch. Avoid using in patients with a personal or family history of long QT syndrome or in patients taking concurrent class IA or III antiarrhythmics or other medications that prolong the QT interval. Use with caution in patients with hypokalemia, hypomagnesemia, or clinically unstable cardiac disease, including unstable heart failure, unstable atrial fibrillation, symptomatic bradycardia, or active MI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Buccal film, extended-release and immediate-release injection, transdermal patch: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Misuse or abuse by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film or transdermal system will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death.</b> Misuse by self-injection of buprenorphine or the concomitant use of buprenorphine and benzodiazepines (or other CNS depressants, including alcohol) may result in coma or death. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. If the extended-release injection is discontinued due to respiratory depression, monitor the patient for ongoing respiratory depression for several months due to its extended-release characteristics. Use with caution in patients with compromised respiratory function (eg, chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause adrenal insufficiency (nausea, vomiting, anorexia, fatigue, weakness, dizziness and low blood pressure) or secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; opioids may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel obstruction: Use with caution in patients with a history of ileus or bowel obstruction; buccal film, immediate-release injection, and transdermal patch are contraindicated in patients with known or suspected GI obstruction, including paralytic ileus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma because these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological conditions: Subdermal implant: Use subdermal implants with caution in patients with a history of keloid formation, connective tissue disease (ie, scleroderma), or history of recurrent MRSA infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use buccal film and sublingual tablet with caution in patients with moderate hepatic impairment; dosage adjustment recommended in severe hepatic impairment. Use immediate-release injection with caution in patients with severe impairment. Subdermal implants should not be used in patients with preexisting moderate to severe hepatic impairment. Transdermal patch should not be used in patients with severe hepatic impairment; consider alternative therapy with more flexibility for dosing adjustments. Patients with preexisting moderate or severe hepatic impairment are not candidates for the extended-release injection. If moderate or severe impairment develops during treatment with the extended-release injection, continue with caution and monitor for toxicity for several months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral mucositis: Buccal film: Oral mucositis may lead to more rapid absorption and higher buprenorphine plasma levels; reduce dose in patients with oral mucositis and monitor closely for signs and symptoms of toxicity or overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines and other CNS depressants: <b>[US Boxed Warning]: </b><b>Buccal film, extended-release and immediate-release injection, transdermal patch: <b>Concomitant use of benzodiazepines or other CNS depressants, including alcohol and opioids, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of opioids and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. </b></b>Prohibiting medication-assisted treatment of opioid use disorder may increase the risk of morbidity and mortality, therefore patients should be educated on the risks of concomitant use with benzodiazepines, sedatives, opioid analgesics, and alcohol. Strategies should be developed to manage use of prescribed or illicit benzodiazepines or other CNS depressants at initiation of or during treatment with buprenorphine; adjustments to induction procedures and additional monitoring may be required. If appropriate, delay or omit buprenorphine dose if a patient is sedated at time of buprenorphine dosing. Discontinuation of benzodiazepines or other CNS depressants is preferred; gradual tapering of benzodiazepine or other CNS depressant, decreasing to lowest effective dose, or monitoring in a higher level of care for taper may be appropriate. Benzodiazepines are not the treatment of choice for anxiety or insomnia for patients in buprenorphine treatment; make sure patients are appropriately diagnosed and consider alternative medications for anxiety and insomnia prior to coadministration of benzodiazepines and buprenorphine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for life-threatening respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; may be more sensitive to adverse effects (eg, life-threatening respiratory depression). In chronic pain, monitor opioid use closely in this age group due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: Buccal film, extended-release and immediate-release injection, transdermal patch: <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal withdrawal syndrome and ensure that appropriate treatment will be available. </b>Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release injection: <b>[US Boxed Warning]: Serious harm or death could result if extended-release injection is administered IV. The injection forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thromboembolic events, including life-threatening pulmonary emboli if administered IV. Because of the risk of serious harm or death that could result from IV self-administration, buprenorphine extended-release injection is only available through a restricted program called the Sublocade REMS Program. Health care settings and pharmacies that order and dispense buprenorphine extended-release injection must be certified in this program and comply with the REMS requirements. </b>Administer via subcutaneous route only. Do not administer IM or IV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subdermal implant: <b>[US Boxed Warning]: Insertion and removal of implant are associated with the risk of implant migration, protrusion, and expulsion. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion in the upper arm. Additional complications may include local migration, protrusion, and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion. Because of the risks associated with insertion and removal, buprenorphine implant is available only through a restricted program. All health care providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing buprenorphine implants. Patients must be monitored to ensure that the implant is removed by a health care provider certified to perform insertions.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: To properly dispose of transdermal patch, fold it over on itself and flush down the toilet; alternatively, seal the used patch in the provided Patch-Disposal Unit and dispose of in the trash. Avoid exposure of application site and surrounding area to direct external heat sources (eg, heating pads, electric blankets, heat or tanning lamps, hot baths/saunas, hot water bottles, direct sunlight). Buprenorphine release from the patch is temperature-dependent and may result in overdose. Patients who experience fever or increase in core temperature should be monitored closely and adjust dose if signs of respiratory depression or CNS depression occur. Application-site reactions, including rare cases of severe reactions (eg, vesicles, discharge, &quot;burns&quot;), have been observed with use; onset varies from days to months after initiation; patients should be instructed to report severe reactions promptly and discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disposal: Extended-release injection and subdermal implant: Handle the removed depots or implants with adequate security, accountability, and proper disposal, per facility procedure for a Schedule III drug product, and per applicable federal, state, and local regulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: Buccal film, extended-release and immediate-release injection, transdermal patch: <b>[US Boxed Warning]: Use exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient's risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with an increased risk for misuse include younger age and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]). The misuse of buccal film by swallowing or of transdermal patch by placing it in the mouth, chewing it, swallowing it, or using it in ways other than indicated may cause choking, overdose, and death.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental ingestion: Buccal film, transdermal patch: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of buprenorphine.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute pain: When using buprenorphine for treatment of opioid dependence, treat acute pain with nonopioid analgesics whenever possible. If treatment with a high-affinity full opioid analgesic is required, monitor closely for respiratory depression because high doses may be necessary to achieve pain relief.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Buccal film, transdermal patch: Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; should not be used for as-needed pain relief. Therapy with the buccal film or transdermal patch is not appropriate for use in the management of addictions. When used for chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults, opioids should <b>not</b> be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Subdermal implant: Not appropriate for patients who are new to treatment or have not sustained prolonged clinical stability on buprenorphine &le;8 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Extended-release injection and sublingual tablet: There is no maximum recommended duration for maintenance treatment of opioid addiction; patients may require treatment indefinitely. Advise patients of the potential to relapse to illicit drug use following discontinuation of opioid agonist/partial agonist medication-assisted treatment. If the extended-release injection is discontinued or the depot is removed, monitor the patient for several months for signs and symptoms of withdrawal. After steady-state has been achieved (4 to 6 months), patients discontinuing extended-release injections may have detectable plasma levels of buprenorphine for 12 months or longer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal pain regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention. When switching patients from buprenorphine to naltrexone, do not initiate naltrexone until 7 to 14 days after buprenorphine discontinuation. No time delay is required when switching patients from buprenorphine to methadone (Kampman [ASAM 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Partial opioid agonist and mixed opioid agonist/antagonist overdose: Reversal of partial opioid agonists or mixed opioid agonist/antagonists (eg, buprenorphine, pentazocine) may be incomplete and large doses of naloxone may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: In patients undergoing elective surgery (excluding caesarean section), discontinuation of buprenorphine 24 to 36 hours before anticipated need for surgical anesthesia may be considered. Short-acting opioids may be given during and/or after surgery. In patients unable to abruptly discontinue buprenorphine prior to surgery, full opioid agonists may be added to the buprenorphine to maintain proper anesthesia; however, increased doses may be required to overcome buprenorphine receptor blockade. If opioid therapy is required as part of anesthesia, patients should be continuously monitored in an anesthesia care setting by persons not involved in in the conduct of the surgical or diagnostic procedure. This guidance applies to anyone who has been treated with extended release buprenorphine injection within the past 6 months. The decision whether to discontinue buprenorphine prior to elective surgery should be made in consultation with the surgeon and anesthesiologist (Kampman [ASAM 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of opioid agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms and is not recommended; taper dose gradually when discontinuing. Withdrawal signs and symptoms will be delayed in patients who discontinue the extended-release injection or have it removed; transmucosal buprenorphine may be needed to treat withdrawal in these patients. Tablets, which are used for induction treatment of opioid dependence, should not be started until objective and clear signs of moderate withdrawal are evident. If subdermal implants are not immediately replaced in contralateral arm after removal, maintain patients on their previous dosage of sublingual buprenorphine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143094\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143025\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12918&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Buprenorphine. Management: Advise patients receiving buprenorphine about the increased risk of CNS depression if they consume alcohol.  Consider alternatives to buprenorphine for opioid addiction treatment in patients who are dependent on alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Buprenorphine may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Buprenorphine.  Management: Avoid this combination in patients un-boosted atazanavir due to possible decreased atazanavir concentrations.  This combination is not contraindicated in patients also receiving ritonavir, but monitoring for buprenorphine toxicity is recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May decrease the serum concentration of Buprenorphine. Boceprevir may increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: Buprenorphine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Opioids (Mixed Agonist / Antagonist) may diminish the analgesic effect of Opioid Analgesics.  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<b> Exceptions: </b>Buprenorphine; Butorphanol; Meptazinol; Nalbuphine; Pentazocine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the therapeutic effect of Buprenorphine. This combination may also induce opioid withdrawal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): Buprenorphine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143041\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure appropriate treatment will be available.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Buprenorphine crosses the placenta; buprenorphine and norbuprenorphine can be detected in newborn serum, urine, and meconium following in utero exposure (CSAT 2004). Based on available data, an increased risk of major malformations has not been observed. Following chronic opioid therapy in pregnancy, adverse events in the newborn (including withdrawal) may occur; monitoring of the neonate is recommended. The minimum effective dose should be used if opioids are needed (Chou 2009). The onset of withdrawal in infants of women receiving buprenorphine during pregnancy ranged from day 1 to day 8 of life, most occurring on day 1. Symptoms of withdrawal may include agitation, apnea, bradycardia, convulsions, hypertonia, myoclonus, respiratory depression, and tremor. Based on available data, there does not appear to be a dose-response relationship with the incidence of neonatal abstinence syndrome.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Buprenorphine is currently considered an alternate treatment for pregnant women who need therapy for opioid addiction (CSAT 2004; Dow 2012; Kampman [ASAM 2015]); however, use in pregnancy for this purpose is increasing (ACOG 2012; Soyka 2013). Because dose adjustments cannot be made, it may not be appropriate to initiate use of the implant in pregnant women; women who become pregnant while using the implant should be closely monitored. Buprenorphine should not be used to treat pain during labor. Women receiving buprenorphine for the treatment of addiction should be maintained on their daily dose of buprenorphine in addition to receiving the same pain management options during labor and delivery as opioid-naive women; maintenance doses of buprenorphine will not provide adequate pain relief. Opioid agonist-antagonists should be avoided for the treatment of labor pain in women maintained on buprenorphine due to the risk of precipitating acute withdrawal. In addition, buprenorphine should not be given to women in labor taking methadone (ACOG 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Amenorrhea may develop secondary to substance abuse; pregnancy may occur following the initiation of buprenorphine maintenance treatment. Contraception counseling is recommended to prevent unplanned pregnancies (Dow 2012). Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction or infertility (Brennan 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051378\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pain relief, respiratory rate, mental status, blood pressure; liver enzymes (baseline and periodic), symptoms of withdrawal, CNS depression, application site reactions (transdermal patch)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and with consideration for re-checking at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143019\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Buprenorphine exerts its analgesic effect via high-affinity binding to mu opiate receptors in the CNS; displays partial mu agonist and weak kappa antagonist activity. Due to it being a partial mu agonist, its analgesic effects plateau at higher doses and it then behaves like an antagonist. The extended-release formulation is injected subcutaneously as a liquid; subsequent precipitation following injection results in a solid depot which will gradually release buprenorphine via diffusion and biodegradation of the depot.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143037\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Analgesic: Immediate-release IM: &ge;15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Immediate-release IM: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate-release IM: &ge;6 hours; Extended-release SubQ: 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Immediate-release IM and SubQ: 30% to 40%. Application of a heating pad onto the transdermal system may increase blood concentrations of buprenorphine 26% to 55%. Ingestion of liquids decreases systemic exposure to buprenorphine from buccal film by 23% to 37%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: CSF concentrations are ~15% to 25% of plasma concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premature neonates (GA: 27 to 32 weeks): 6.2 &plusmn; 2.1 L/kg (Barrett 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 7 years: 3.2 &plusmn; 2 L/kg (Olkkola 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 97 to 187 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: High (~96%, primarily to alpha- and beta globulin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic via N-dealkylation by CYP3A4 to norbuprenorphine (active metabolite), and to a lesser extent via glucuronidation by UGT1A1 and 2B7 to buprenorphine 3-O-glucuronide; the major metabolite, norbuprenorphine, also undergoes glucuronidation via UGT1A3; extensive first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability (relative to IV administration): Buccal film: 46% to 65%; Immediate-release IM: 70%; Sublingual tablet: 29%; Transdermal patch: ~15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates (GA: 27 to 32 weeks): Immediate-release IV: 20 &plusmn; 8 hours (Barrett 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 4 to 7 years: Immediate-release IV: ~1 hour (Olkkola 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IV: 2.2 to 3 hours; Buccal film: 27.6 &plusmn; 11.2 hours; Apparent terminal half-life: Sublingual tablet: ~37 hours; Transdermal patch: ~26 hours. <b>Note:</b> Extended elimination half-life for sublingual administration may be due to depot effect (Kuhlman 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Buccal film: 2.5 to 3 hours; Extended-release SubQ: 24 hours, with steady state achieved after 4 to 6 months; Subdermal implant: 12 hours after insertion, with steady state achieved by week 4; Sublingual: 30 minutes to 1 hour (Kuhlman 1996); Transdermal patch: Steady state achieved by day 3</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~70%; 33% as unchanged drug; 5% as conjugated drug; 21% as norbuprenorphine; and 2% as conjugated norbuprenorphine); urine (27% to 30%; 1% as unchanged drug; 9.4% as conjugated drug; 2.7% as norbuprenorphine; and 11% as conjugated norbuprenorphine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Related to hepatic blood flow</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premature neonates (GA: 27 to 32 weeks): 0.23 &plusmn; 0.07 L/hour/kg (Barrett 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 7 years: 3.6 &plusmn; 1.1 L/hour/kg (Olkkola 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.78 to 1.32 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051388\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Equianalgesic doses (parenteral): Buprenorphine 0.3 mg = morphine 10 mg; buprenorphine has a longer duration of action than morphine </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Symptoms of overdose include CNS and respiratory depression, pinpoint pupils, hypotension, and bradycardia; treatment is supportive; naloxone may have limited effects in reversing respiratory depression; doxapram has also been used as a respiratory stimulant. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20209938\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 0.075 mg/mL solution can be made using the 0.3 mg/mL injection, 95% ethanol, and simple syrup. Add 1.26 mL of 95% ethanol to 0.3 mg buprenorphine obtained from an 0.3 mg/1 mL ampule, mix well, and add quantity of simple syrup sufficient to obtain 4 mL (final volume). Solution is stable under refrigeration and at room temperature for 30 days when stored in amber glass bottles and for 7 days when stored in oral syringes (Anagnostis 2011; Anagnostis 2013).</p>\n    <div class=\"reference\">Anagnostis EA, Sadaka RE, Sailor LA, et al, &quot;Formulation of Buprenorphine for Sublingual Use in Neonates,&quot; <i>J Pediatr Pharmacol Ther</i>, 2011, 16(4):281-4.<span class=\"pubmed-id\">22768012</span></div>\r\n\n    <div class=\"reference\">Anagnostis EA, personal communication, March 2013.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989198\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Film</b> (Belbuca Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (60): $364.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (60): $364.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (60): $572.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mcg (60): $777.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (60): $829.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mcg (1): $14.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mcg (60): $898.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Implant</b> (Probuphine Implant Kit Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">74.2 mg (4): $5,940.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Buprenorphine Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/hr (4): $231.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mcg/hr (4): $322.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/hr (4): $347.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mcg/hr (4): $500.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg/hr (4): $613.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Butrans Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/hr (4): $322.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mcg/hr (4): $451.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/hr (4): $483.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mcg/hr (4): $697.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg/hr (4): $855.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Buprenex Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/mL (1 mL): $18.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Buprenorphine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/mL (1 mL): $14.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Sublocade Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/0.5 mL (0.5 mL): $1,896.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/1.5 mL (1.5 mL): $1,896.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Buprenorphine HCl Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (30): $135.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $253.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143042\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acron (BD);</li>\n      <li>Addictex (TR);</li>\n      <li>Addnok (IN);</li>\n      <li>Brospina (MX);</li>\n      <li>Bugesic (BD);</li>\n      <li>Bupensan (EE, LT);</li>\n      <li>Bupine (IN);</li>\n      <li>Bupralex (AU);</li>\n      <li>Bupren (AR, UA);</li>\n      <li>Buprex (ES);</li>\n      <li>Butrans (GB, IE, IL);</li>\n      <li>Dorfene (PK);</li>\n      <li>Ednok (UA);</li>\n      <li>Feliben (ES);</li>\n      <li>Gabup (GB);</li>\n      <li>Hapoctasin (GB);</li>\n      <li>Nalgesic (BD);</li>\n      <li>Nopan (RU);</li>\n      <li>Norphin (IN);</li>\n      <li>Norspan (CN, ES, SK, VN);</li>\n      <li>Norspan Patch (AU, DE, DK, EE, FI, HK, KR, NO, NZ, PH);</li>\n      <li>Norspan Tape (JP);</li>\n      <li>Pentorel (IN);</li>\n      <li>Restiva (AR);</li>\n      <li>SBT (IL);</li>\n      <li>Shumeifen (CN);</li>\n      <li>Sovenor (MY, SG);</li>\n      <li>Subutex (AE, AT, AU, BE, BG, CH, CZ, DE, DK, FR, GR, HR, ID, IE, IL, IS, LU, LV, MT, NO, PT, QA, SE, TW);</li>\n      <li>Temgesic (AE, AT, BE, BF, BH, BJ, BR, CH, CI, CY, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, HK, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PK, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Tidigesic (IN);</li>\n      <li>Transtec (BE, CH, CL, CO, DE, DK, EC, ES, GB, HN, HR, HU, IE, IT, MX, NL, NO, PE, PL, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Health Care for Underserved Women and American Society of Addiction Medicine, &quot;ACOG Committee Opinion No. 524: Opioid Abuse, Dependence, and Addiction in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2012, 119(5):1070-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/22525931/pubmed\" target=\"_blank\" id=\"22525931\">22525931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aurilio C, Ceccarelli I, Pota V, et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. <i>Endocr J</i>. 2011;58(12):1071-1078.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/21937837/pubmed\" target=\"_blank\" id=\"21937837\">21937837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrett DA, Simpson J, Rutter N, et al, &ldquo;The Pharmacokinetics and Physiological Effects of Buprenorphine Infusion in Premature Neonates,&rdquo; <i>Br J Clin Pharmacol</i>, 1993, 36(3):215-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/ 9114907 /pubmed\" target=\"_blank\" id=\" 9114907 \"> 9114907 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingm&uuml;ller  D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. <i>J Clin Endocrinol Metab</i>. 2005;90(1):203-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/15483091/pubmed\" target=\"_blank\" id=\"15483091\">15483091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3) (Suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Center for Substance Abuse Treatment (CSAT), <i>Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction</i>, Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04&#8208;3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &quot;Clinical Guidelines For the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&quot;<i> J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain - United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines For Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamunen K, Olkkola KT, and Maunuksela EL, &ldquo;Comparison of the Ventilatory Effects of Morphine and Buprenorphine in Children,&rdquo; <i>Acta Anaesthesiol Scand</i>, 1993, 37(5):449-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/8356856/pubmed\" target=\"_blank\" id=\"8356856\">8356856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft WK, Dysart K, Greenspan JS, et al, &quot;Revised Dose Schema of Sublingual Buprenorphine in the Treatment of the Neonatal Opioid Abstinence Syndrome,&quot; <i>Addiction</i>, 2011, 106(3):574-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/20925688/pubmed\" target=\"_blank\" id=\"20925688\">20925688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft WK, Gibson E, Dysart K, et al, &quot;Sublingual Buprenorphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Trial,&quot; <i>Pediatrics</i>, 2008, 122(3):e601-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/18694901/pubmed\" target=\"_blank\" id=\"18694901\">18694901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuhlman JJ Jr, Lalani S, Magluilo J Jr, et al, &quot;Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine,&quot; <i>J Anal Toxicol</i>, 1996, 20(6):369-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/8889672/pubmed\" target=\"_blank\" id=\"8889672\">8889672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maunuksela EL, Korpela R, and Olkkola KT, &ldquo;Comparison of Buprenorphine With Morphine in the Treatment of Postoperative Pain in Children,&rdquo; <i>Anesth Analg</i>, 1988, 67(3):233-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/ 3344976 /pubmed\" target=\"_blank\" id=\" 3344976 \"> 3344976 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maunuksela EL, Korpela R, and Olkkola KT, &ldquo;Double-Blind, Multiple-Dose Comparison of Buprenorphine and Morphine in Postoperative Pain of Children,&rdquo; <i>Br J Anaesth</i>, 1988, 60(1):48-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/3337794/pubmed\" target=\"_blank\" id=\"3337794\">3337794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, and Academy Of Breastfeeding Medicine, &quot;ABM Cinical Protocol #15: Analgesia and Anesthesia For the Breastfeeding Mother, Revised 2012,&quot; <i>Breastfeed Med</i>, 2012, 7(6):547-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olkkola KT, Leijala MA, and Maunuksela EL, &ldquo;Paediatric Ventilatory Effects of Morphine and Buprenorphine Revisited,&rdquo; <i>Paediatr Anaesth</i>, 1995, 5(5):303-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/7489472/pubmed\" target=\"_blank\" id=\"7489472\">7489472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olkkola KT, Maunuksela EL, and Korpela R, &ldquo;Pharmacokinetics of Intravenous Buprenorphine in Children,&rdquo; <i>Br J Clin Pharmacol</i>, 1989, 28(2):202-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/2775626/pubmed\" target=\"_blank\" id=\"2775626\">2775626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soyka M, &quot;Buprenorphine Use in Pregnant Opioid Users: A Critical Review,&quot; <i>CNS Drugs</i>, 2013, 27(8):653-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/23775478/pubmed\" target=\"_blank\" id=\"23775478\">23775478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, and Center for Substance Abuse Treatment (CSAT ), &ldquo;Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction,&rdquo; 2005. Available at <a href=\"http://kap.samhsa.gov/products/tools/keys/pdfs/KK_40.pdf\" target=\"_blank\">http://kap.samhsa.gov/products/tools/keys/pdfs/KK_40.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Welsh CJ, Suman M, Cohen A, et al, &ldquo;The Use of Intravenous Buprenorphine for the Treatment of Opioid Withdrawal in Medically Ill Hospitalized Patients,&rdquo; <i>Am J Addict</i>, 2002, 11(2): 135-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buprenorphine-pediatric-drug-information/abstract-text/12028743/pubmed\" target=\"_blank\" id=\"12028743\">12028743</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12918 Version 226.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50624628\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11370705\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F143056\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F143057\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051379\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F16425058\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051372\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F143032\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F143016\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46925041\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F143102\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11217368\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11370707\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051383\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F143050\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051382\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F143110\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F143107\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F143038\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F143020\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F143094\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F143025\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F143041\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051378\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F143019\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F143037\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051388\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F20209938\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989198\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F143042\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12918|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">Buprenorphine: Drug information</a></li><li><a href=\"topic.htm?path=buprenorphine-patient-drug-information\" class=\"drug drug_patient\">Buprenorphine: Patient drug information</a></li></ul></div></div>","javascript":null}